MaxCyte, Inc.
MXCT
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assaysā¦ read more
Healthcare
Medical Devices
4 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.58
Price+4.64%
$0.07
1Y
Price
Market Cap
$168.498m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-130.3%
EBITDA Margin-145.3%
Net Profit Margin-122.7%
Free Cash Flow MarginRevenue
$35.754m
-7.4%
1y CAGR-6.9%
3y CAGR+2.5%
5y CAGREarnings
-$44.772m
-9.0%
1y CAGR-36.3%
3y CAGR-26.8%
5y CAGREPS
-$0.43
-10.3%
1y CAGR-36.8%
3y CAGR-24.2%
5y CAGRBook Value
$190.723m
$219.750m
Assets$29.027m
Liabilities$18.507m
DebtDebt to Assets
8.4%
-0.4x
Debt to EBITDAFree Cash Flow
-$38.265m
-30.8%
1y CAGR-7.4%
3y CAGR-37.9%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company